Skip to main content

Table 2 Characteristics of laboratory outcomes in different groups

From: Effect of letrozole cotreatment in progestin-primed ovarian stimulation on IVF/ICSI outcomes in POSEIDON group 3 and 4 poor responders: a retrospective cohort study

Variables

POSEIDON Group 3

P value

POSEIDON Group 4

P value

PPOS group

n = 78

PPOS + LE group

n = 111

PPOS group

n = 154

PPOS + LE group

n = 214

Ovarian stimulation duration (days)

9.23 ± 1.73

9.14 ± 1.41

0.705

9.16 ± 1.86

9.24 ± 1.89

0.678

Total gonadotropin dose (IU)

2718.27 ± 732.28

2906.08 ± 649.56

0.065

2899.24 ± 785.59

2968.98 ± 661.10

0.371

Premature LH surge rate, n (%)

3/78

(3.85)

1/111

(0.90)

0.383

7/154

(4.55)

9/214

(4.21)

0.875

E2 level on the trigger day (ng/ml)

960.50

(620.75, 1244.50)

773.00

(509.00, 1088.00)

0.042*

873.00

(560.50, 1213.75)

747.00

(380.00, 1078.75)

0.011*

LH level on the trigger day (mIU/mL)

3.32

(1.67, 4.35)

3.71

(2.79, 4.79)

0.012*

3.54

(2.30, 5.94)

4.19

(2.96, 6.05)

0.036*

Endometrial thickness (mm)

7.9

(6.9, 9.6)

7.6

(6.3, 9.4)

0.228

7.2

(6.4, 8.2)

7.7

(6.1,9.0)

0.250

Dominant follicle ≥ 14 mm

3.0

(2.0,5.0)

3.0

(2.0,5.0)

0.217

3.0

(2.0, 4.0)

3.0

(2.0,4.0)

0.089

No. of oocytes retrieved

3.5

(2.0,5.0)

4.0

(3.0, 6.0)

0.127

2.0

(1.3, 4.0)

3.0

(2.0, 5.0)

 < 0.001*

No. of MII oocytes

3.0

(2.0, 5.0)

3.0

(2.0,5.0)

0.176

2.0

(1.0, 3.8)

3.0

(2.0, 5.0)

 < 0.001*

No. of 2PN embryos

2.0

(1.0, 4.0)

2.0

(1.0, 4.0)

0.236

2.0

(1.0, 3.0)

2.0

(1.0, 3.0)

0.026*

No. of available embryos

1.0

(1.0, 2.0)

2.0

(1.0, 3.0)

0.356

1.0

(0.0, 2.0)

1.0

(1.0, 2.0)

0.211

Mature oocyte rate, n (%)

263/308

(85.39)

411/482

(85.27)

0.963

415/479

(86.63)

760/853

(89.10)

0.182

2PN embryo rate (%), n (%)

187/263

(71.10)

292/411

(71.05)

0.987

297/415

(71.57)

504/760

(66.32)

0.065

2PN cleavage rate (%), n (%)

183/187

(97.86)

287/292

(98.29)

1.000

288/297

(96.97)

480/504

(95.24)

0.467

Available embryo rate (%), n (%)

132/183

(72.13)

203/287

(70.73)

0.744

210/288

(72.92)

318/480

(66.25)

0.054

Cycle cancellation rate (%), n (%)

17/78

(21.80)

14/111

(12.61)

0.093

42/154

(27.27)

39/214

(18.22)

0.039*

  1. Data were presented as mean ± SD, median (25th percent, 75th percent) and n (%)
  2. *P < 0.05
  3. E2, Estradiol; LH, Luteinizing hormone; 2PN, two pronuclei
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us